Amylin deal

The San Diego company extended its collaboration with Glaxo Holdings plc for the development of medicines to treat diabetes, high blood pressure and obesity. In October 1991 the companies entered into a three-year agreement to study the effects of compounds that block the actions of the pancreatic hormone amylin. ...